Last reviewed · How we verify
NCT04883164
Immunity After COVID-19 Vaccination
trial testing Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples in Immunity to COVID-19 in 300 participants. Status unknown.
31 March 2023
Quick facts
| Lead sponsor | Plexision |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 27 April 2021 |
| Primary completion | 31 March 2023 |
| Estimated completion | 31 March 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cellular and antibody response to spike antigens of SARS-CoV-2 in both groups in peripheral blood samples
Conditions studied
- Immunity to COVID-19 — all drugs for Immunity to COVID-19 →
Sponsor
Plexision
Who can join
Adults 18 to 100, any sex, with Immunity to COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the research is to evaluate new blood tests, which measure immunity to the COVID-19 coronavirus after vaccination. These tests will be used to measure T-cell and antibody immunity after COVID-19 vaccination. Recent studies show that less than one-fifth of chronically immunosuppressed transplant recipients developed anti-receptor-binding domain antibodies after the first dose of the Pfizer vaccine (Boyarski, 2021). ood sampling at periodic intervals. These samples will be used to measure T-cell and antibody immunity to the COVID-19 coronavirus.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04883164
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Plexision trials
Trials by the same sponsor.
- NCT03916822 — Cell-based Assays for Antibody-mediated Transplant Rejection · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04883164 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Plexision
- Last refreshed: 12 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04883164.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing